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Objective To assess the efficacy of chloroquine and sulfadoxine/pyrimethamine in the treatment of uncomplicated Plasmodium
falciparum infections in Somalia.
Methods Patients with clinical malaria in Merca, an area of high transmission of the disease, were treated with the standard regimens
of chloroquine (25 mg/kg) or sulfadoxine/pyrimethamine (25 mg sulfadoxine and 1.25 mg pyrimethamine per kg). Similar patients in
Gabiley, an area of low transmission, received the standard regimen of chloroquine. The clinical and parasitological responses were
monitored for 14 days.
Findings Chloroquine treatment resulted in clinical failure in 33% (n = 60) and 51% (n = 49) of the patients in Merca and Gabiley
respectively. There were corresponding parasitological failures of 77% RII/RIII and 35% RII/RIII. Patients who experienced clinical
failure had significantly higher initial parasitaemia than those in whom there was an adequate clinical response, both in Merca (t = 2.2;
P < 0.04) and Gabiley (t = 2.8; P < 0.01). With the sulfadoxine/pyrimethamine treatment, 98% (n = 50) of the patients achieved an
adequate clinical response despite a parasitological failure rate of 76% RII/RIII.
Conclusion Chloroquine should no longer be considered adequate for treating clinical falciparum malaria in vulnerable groups in the
areas studied. Doubts about the therapeutic life of sulfadoxine/pyrimethamine in relation to malaria are raised by the high levels of
resistance in the Merca area and underline the need to identify suitable alternatives.
Keywords Malaria, Falciparum/drug therapy; Chloroquine/therapeutic use; Sulfadoxine/therapeutic use; Pyrimethamine/therapeutic
use; Antimalarials/therapeutic use; Drug resistance; Treatment outcome; Treatment failure; Somalia (source MeSH, NLM ).
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Introduction
Chloroquine-resistant Plasmodium falciparum was first detected
in Somalia in 1986, when resistance occurred in low frequency
and degree in a semi-immune population (1). By 1989 the
prevalence of chloroquine resistance had reached 30% and
70% among semi-immune and less immune populations,
respectively (2, 3). Resistance evidently developed more
rapidly both in frequency and degree than in neighbouring
Ethiopia, where it emerged at about the same time (4) and
where the drug achieved a better response (5). In contrast,
chloroquine resistance in Kenya reached high levels, forcing
the abandonment of the drug as the first-line treatment for
uncomplicated malaria (6).
The spread and intensification of resistance to anti-
malarials in Somalia has possibly been exacerbated by the
conflict that has continued since 1991, causing the collapse of
the health care infrastructure and the displacement of large
numbers of people. The therapeutic usefulness of chloroquine
therefore needs to be reassessed.
In all previous in-vivo studies the assessment of
antimalarial drug responses was based solely on parasitological
criteria. In areas of intense malaria transmission and high
communal immunity, however, these criteria may be inade-
quate, and the clinical efficacy of commonly used antimalarials
should be ascertained.
The purpose of this study is to assess the
therapeutic efficacy of chloroquine and of sulfadoxine/
pyrimethamine against uncomplicated falciparum infec-
tions in Somalia. The implications for malaria treatment
are discussed.
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Methods
Study areas
The study was conducted between July and September 1997 in
the Merca area of south Somalia and in the Gabiley area of the
north-western region of the country. There is a mesoendemic
pattern of malaria in the Merca area (7), which contains two
large villages and three small ones, all located within a radius of
10 km. During 1997 this area experienced prolonged rains and
flooding. In the Gabiley area, malaria transmission is low,
seasonal peaks occurring after the rainy seasons in April and
July. Low rainfall and drought often occur and the years with
exceptionally heavy rains lead tomalaria epidemics. This results
in low or zero immunity in the population. As scarce rains and
drought are common in the area, seasonal exacerbations
leading to malaria epidemics occur.
Patients
Before enrolment a detailed history was obtained from adult
patients or from the parents or guardians of child patients, and
a physical examination was performed. Patients who were
pregnant or who had severe malaria or other concomitant
disease were excluded. Informed consent was obtained from
the patients or their parents or guardians. The study was
approved by the health authorities and village elders of the
study areas. In the Gabiley area, the Ministry of Health and the
Director of Planning approved the study, and the Head of
Malaria Control was the team leader.
Patients were recruited in the villages of Wagade,
Mushani and Malable in the Merca area and in a hospital
outpatient department in the Gabiley area. The inclusion
criteria were: symptoms compatible with clinical malaria with
fever (5 37.5 oC) or a history of fever within the previous 24–
48 hours, monoinfection with P. falciparum and a parasite
density of 1000 or more asexual parasites/ml, and no history of
antimalarial intake for the previous two weeks. In the Merca
area of high malaria transmission, 68 and 53 patients were
recruited for chloroquine and sulfadoxine/pyrimethamine
treatment respectively. Eight and three patients in the
respective groups were excluded because they missed
follow-up schedules. Five of the 54 patients from the Gabiley
area of low malaria transmission were excluded for the same
reason. Children accounted for one-third of the patients in the
Gabiley area and for 90% of the chloroquine group in the
Merca area (Table 1).
Treatment and follow-up
The efficacy of chloroquine was assessed at both sites and that
of sulfadoxine/pyrimethamine was assessed only in the Merca
area, by means of a modified WHO 14-day in-vivo protocol
(8). The allocation of chloroquine or sulfadoxine/pyrimetha-
mine to every patient inWagade orMushaniwas determined by
tossing a coin, and individuals in Malable village were allocated
one or other treatment (random allocation). Chloroquine
(Pharmacia, Sweden) was administered at 10 mg per kg body
weight on days 0 and 1, and at 5 mg per kg on day 2.
Sulfadoxine/pyrimethamine (Hoffmann – La Roche, Switzer-
land) was given as a single dose at 25 mg sulfadoxine and
1.25 mg pyrimethamine per kg. All medications were given
under supervision. The patients were monitored on days
0, 1, 2, 3, 7 and 14 for clinical responses, and on days 0, 3, 7
and 14 for parasitological responses. They were asked to report
at any time if symptoms recurred. Thick blood smears were
taken, stained with Giemsa’s stain and read in accordance with
theWHOprotocol (8). The clinical responseswere classified as
follows: (i) early clinical failure if the symptoms persisted or
deteriorated within the first three days in the presence of
parasitaemia; (ii) late clinical failure if there was a recurrence of
symptoms and fever with a measurable axillary temperature of
37.5 oC or above on the fourth day or later in the presence of
parasitaemia; and (iii) adequate clinical response if the symptoms
cleared within the first three days, irrespective of the presence
of parasitaemia, and did not recur.
Parasitological failure was defined as the presence of
asexual parasites on day 7 or day 14. The responses were
classified as RIII or RII resistance if the parasite densities on
day 3 were at least 25% or less than 25% respectively of the
initial parasitaemia, i.e. on day 0, and remained positive on day
7, or as RI resistance if the parasitaemia cleared on day 7 but
reappeared on day 14. The absence of parasitaemia on day
7 and day 14 was classified as the S response. Children who
met the criteria for clinical failure were treated with an
alternative drug and were not followed up again.
Statistical analysis
Geometrical means of parasite densities were calculated for
persons with detectable asexual forms of P. falciparum.
Proportions were compared by means of the w2 test with
Yates’ correction or bymeans of Fisher’s exact test. Student’s t-
test was applied to continuous data.
Results
Clinical response
The treatment outcomes are summarized in Table 2. In the
Merca area, 67% of the chloroquine group showed an
adequate clinical response and 33% experienced an initial
clinical improvement, followed by the recurrence of fever
between day 7 and day 14, indicating late clinical failure. The
six adults all achieved adequate clinical response. In the
Gabiley area, 35% of the patients experienced early clinical
Table 1. Baseline characteristics of patients in Gabiley and
Merca areas
Parameters Gabiley area Merca area
Chloroquine Chloroquine Sulfadoxine/
n = 49 n = 60 pyrimethamine
n = 50
Children (number) 16 54 50
Mean age in years ± SDa 6.3 ± 4.0 4.8 ± 3.6 4.6 ± 3.0
Adults (number) 33 6 0
Mean age in years ± SD 28.33 ± 13.0 26 ± 9.1 NAb
Male (%) 57 45 60
Axillary tempera-
ture537.5 oC (%)
77.6 70.0 68.0
Parasitaemia
Geometric mean
parasite density
15 513
(7631–17 371)c
6507
(4332–9774)
3870
(2709–5528)
a SD = standard deviation.
b NA = not applicable.
c Figures in parentheses are 95% confidence intervals.
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failure, 16% had late clinical failure, and 31% showed an
adequate clinical response. In the remaining nine patients,
parasitaemia was higher on day 7 than on day 3 but the
patients were not yet febrile. These nine patients were given
alternative medication since it was considered unsafe to wait
for the occurrence of clinical symptoms. There was no
difference in clinical response between children and adults in
the Gabiley area. In the Merca area there was an adequate
clinical response in all patients except one in the sulfadoxine/
pyrimethamine group.
Parasitological response
In the chloroquine treatment, 77% of infections in the Merca
area showed RII/RIII responses, 12% showed the RI
response, and only one showed the S response. The remaining
six patients gave positive results on day 7 with low
parasitaemia (mean = 292 asexual parasites/ml; 95%
confidence interval (CI): 153–559) but negative results on
day 14 in what was classified as a late S response. Of the six
adults, two showed S/RI responses and four showed the RII
response. In Gabiley, 35% of the infections exhibited RII/
RIII responses, and 18% and 22% showed RI and
S responses respectively. The parasitological responses of
the remaining 12 subjects were unclassifiable, these patients
having received alternative medication before day 3 because
of deterioration in their clinical condition. There was no
difference in parasitological response between children and
adults in the Gabiley area. In the Merca group there were too
few adults for a meaningful analysis to be made. Among the
sulfadoxine/pyrimethamine group in the Merca area, 76% of
the infections exhibited RII/RIII responses and three showed
late S responses. The S and RI responses were combined
since true recrudescence could not be differentiated from
reinfection, and recrudescence after day 14 (late RI) could not
be detected by the follow-up at 14 days.
In the Merca area, 58% and 60% of the chloroquine-
treated patients with RII and RIII parasitological responses
respectively achieved adequate clinical responses. However,
no such clinical responses were associated with the RII and
RIII infections in the Gabiley area. Of the 40 patients with
adequate clinical responses in the Merca area, 83% were still
parasitaemic on day 14, whereas only 27% of the 15 patients
with similar responses in the Gabiley area were parasitaemic
(P < 0.001, Fisher’s exact test). Patients who experienced
clinical failures had significantly higher initial parasitaemia than
those who achieved adequate clinical responses, both in Merca
(t = 2.2; P < 0.04) and Gabiley (t = 2.8; P < 0.01).
The outcome measures used in this study were
compared with those of the WHO 14-day in vivo protocol
for areas of intense transmission (8). Among the chloroquine-
treated group in the Merca area, four and six patients from the
late clinical failure and adequate clinical response groups
respectively would have been classified as early treatment
failures under the WHO criteria. Nine patients with adequate
clinical responses to sulfadoxine/pyrimethamine would have
been classified as early treatment failures. On day 3 the level of
parasitaemia in all these patients was at least 25% of the initial
value, a criterion for early treatment failure according to the
WHO protocol.
Discussion
The standard regimen of chloroquine failed to produce
adequate clinical responses in 33% and 51% of the patients
in the Merca and Gabiley areas, respectively. In the Gabiley
area over one-third of patients experienced early clinical failure,
whereas there was no early clinical failure in the Merca area. In
contrast, all the patients with clinical failure in the Merca area
had experienced an initial clinical improvement, whether RI,
RII or RIII infections were involved. This suggested that the
clinical impact of chloroquine resistance was reduced by the
relatively early development of immunity resulting from the
intensive contact between humans and parasites which
occurred in this area. The role of immunity in treatment
outcome was underlined by the achievement of adequate
clinical responses by some 60% of the chloroquine-treated
patients with RII/RIII infections in theMerca area. This might
also explain the phenomenon of the late S responders, in which
some patients from the area were parasitaemic on day 7 but had
become negative by day 14 without additional treatment, as
reported by Barat et al. (9). Residual parasites, eventually
cleared by the host’s immune mechanism, might have been
involved (10). The lack of age-related clinical and parasitolo-
gical responses in the Gabiley area could be explained by the
low exposure of the community to malaria. However, the
opposite could be indicated by the clinical improvement
achieved by all six adults in the Merca area, even though two-
thirds of them showed RII responses. Besides immunity, the
degree of initial parasitaemia seems to influence the clinical
outcome of treatment.
The results demonstrated a dramatic increase in the
frequency and degree of chloroquine resistance in the Merca
area in comparison with a prevalence of 30% RII/RIII
responses among asymptomatic subjects in 1989 (2). How-
ever, high levels of chloroquine resistance (70% RII/RIII)
Table 2. Clinical and parasitological responses of P. falciparum
to chloroquine and sulfadoxine/pyrimethamine in Gabiley
and Merca areas
Gabiley area Merca area
Responses Chloroquine Chloroquine Sulfadoxine/
pyrimethamine
No. (%) No. (%) No. (%)
Clinical
Early clinical failure 17 34.7 0 0 0 0
Late clinical failure 8 16.3 20 33.3 1 2.0
Adequate clinical
response
15 30.6 40 66.7 49 98.0
ACR/LCFa 9 18.4 0 0 0 0
Total 49 100 60 100 50 100
Parasitological
S/RIb 20 40.8 14 23.3 12 24.0
RIIc 14 28.6 36 60.0 29 58.0
RIIId 3 6.1 10 16.6 9 18.0
UNCe 12 24.5 0 0 0 0
Total 49 100 60 100 50 100
a Adequate clinical response or late clinical failure.
b Cleared parasitaemia or recurrence of parasitamia during follow-up.
c Parasitaemia on day 3 reduced to <25% of initial level and positive on day 7.
d Parasitaemia on day 3 reduced to525% of initial level and positive on day 7.
e Unclassifiable because of clinical deterioration on day 1 (n = 9) and day 2 (n = 3);
received alternative medication before day 3.
Research
706 Bulletin of the World Health Organization 2002, 80 (9)
among children and immigrants suffering from clinical malaria
were reported from another part of the country in 1988 (3).
Although sulfadoxine/pyrimethamine produced an ade-
quate clinical response in 98% of the patients, an ominously high
degree of parasite resistance (76% RII/RIII) was observed.
Similar clinical efficacy rates have been reported elsewhere in
Africa but atmuch lower rates of parasitological failure (9,11, 12).
In the absence of a functioning treatment policy and regulatory
systems, sulfadoxine/pyrimethamine was made easily accessible
in Somalia, even for rural communities, through aid organizations
and the private market. The high rate of parasitological failure in
the Merca area is not, therefore, surprising, given the relatively
long half-life of sulfadoxine/pyrimethamine, which is likely to
exert undesirable pressure for a considerable time once its
concentration drops below the critical threshold. Drug pressure
associatedwith thewidespread use of sulfa-based antibiotics, e.g.
cotrimoxazole, for the treatment of bacterial infections might
have added to the problem. Ronn et al. (13) observed high levels
of sulfadoxine/pyrimethamine resistance in a Tanzanian com-
munity previously exposed to drug pressure from dapsone/
pyrimethamine and sulfadoxine/pyrimethamine.
Our findings indicate that chloroquine should no longer be
considered satisfactory for treating clinically manifest falciparum
malaria in children, pregnant women and non-immune persons
in the Merca and Gabiley areas. Malaria transmission is unstable
in large parts of Somalia, resulting in little or no communal
immunity. If suitable meteorological conditions were to occur,
treatment failures could lead to devastating epidemics affecting
all age groups (3). The obvious option for a first-line treatment in
such circumstances would normally be that of sulfadoxine/
pyrimethamine, which is already available and in use. However,
the high level of RII/RIII sulfadoxine/pyrimethamine resistance
reported here raises doubts about the therapeutic life span of the
combination in the treatment of malaria. Continuous monitoring
of its clinical efficacy in different parts of the country is therefore
necessary. Chloroquine is being increasingly replaced by
sulfadoxine/pyrimethamine in order to combat uncomplicated
malaria in Africa but clinical failure following the use of this
combination can be expected sooner or later. There is a clear
need to look beyond sulfadoxine/pyrimethamine and to identify
suitable alternatives. n
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Re´sume´
Efficacite´ the´rapeutique de la chloroquine et de la sulfadoxine/pyrime´thamine contre l’infection
a` Plasmodium falciparum en Somalie
Objectif Evaluer l’efficacite´ de la chloroquine et de la sulfadoxine/
pyrime´thamine dans le traitement des infections non complique´es a`
Plasmodium falciparum en Somalie.
Me´thodes Les patients atteints de paludisme clinique dans la
re´gion de Merca, ou` la transmission de la maladie est intense, ont
e´te´ traite´s selon le sche´ma standard par la chloroquine (25 mg/kg)
ou la sulfadoxine/pyrime´thamine (25 mg/kg de sulfadoxine et
1,25 mg/kg de pyrime´thamine). Des patients de meˆmes caracte´-
ristiques mais dans la re´gion de Gabiley, ou` la transmission de la
maladie est faible, ont rec¸u le traitement standard par la
chloroquine. La re´ponse clinique et la re´ponse parasitologique
ont e´te´ suivies pendant 14 jours.
Re´sultats Le traitement par la chloroquine s’est solde´ par un
e´chec clinique chez 33 % des patients (n = 60) dans la re´gion de
Merca et 51 % des patients (n = 49) dans la re´gion de Gabiley. Les
taux d’e´chec parasitologique correspondants (RII/RIII) e´taient
respectivement de 77 % et 35 %. Chez les patients ayant pre´sente´
un e´chec clinique, la parasite´mie initiale e´tait significativement plus
e´leve´e que chez ceux ayant montre´ une re´ponse clinique
satifaisante, aussi bien dans la re´gion de Merca (t = 2,2 ;
p<0,04) que dans celle de Gabiley (t = 2,8 ; p<0,01). Avec la
sulfadoxine/pyrime´thamine, 98 % des patients (n = 50) ont
pre´sente´ une re´ponse clinique satisfaisante malgre´ un taux d’e´chec
parasitologique (RII/RIII) de 76 %.
Conclusion Dans les re´gions e´tudie´es, la chloroquine ne doit
plus eˆtre conside´re´e comme traitement ade´quat du paludisme
clinique a` falciparum dans les groupes vulne´rables. Les hauts
niveaux de re´sistance observe´s dans la re´gion de Merca
soule`vent des doutes quant a` la dure´e de vie the´rapeutique de
la sulfadoxine/pyrime´thamine pour le traitement du paludisme
et soulignent la ne´cessite´ d’identifier des alternatives
convenables.
Resumen
Eficacia terape´utica de la cloroquina y la sulfadoxina/pirimetamina contra la infeccio´n por Plasmodium
falciparum en Somalia
Objetivo Evaluar la eficacia de la cloroquina y la sulfadoxina/
pirimetamina en el tratamiento de las infecciones por Plasmodium
falciparum sin complicaciones en Somalia.
Me´todos Se trato´ a pacientes con paludismo clı´nico de Merca, un
a´rea de alta transmisio´n de la enfermedad, con las pautas esta´ndar
de cloroquina (25 mg/kg) o sulfadoxina/pirimetamina (25 mg/kg de
sulfadoxina y 1,25 mg/kg de pirimetamina). Se administro´ tambie´n el
re´gimen ordinario de cloroquina a pacientes comparables de
Gabiley, una zona de transmisio´n baja. La respuesta clı´nica y
parasitolo´gica se controlo´ por espacio de 14 dı´as.
Resultados El tratamiento con cloroquina no tuvo efecto clı´nico en
el 33% (n = 60) y el 51% (n = 49) de los pacientes de Merca y
Gabiley, respectivamente. Los casos correspondientes sin efecto
parasitolo´gico (fracasos RII/RIII) representaron el 77% y el 35%. Los
pacientes que no respondieron clı´nicamente presentaron una
parasitemia inicial significativamente mayor que la de quienes sı´ lo
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hicieron, tanto en Merca (t = 2,2; P < 0,04) como en Gabiley (t = 2,8;
P < 0,01). Con el tratamiento de sulfadoxina/pirimetamina, el 98%
(n = 50) de los pacientes respondieron favorablemente a nivel clı´nico,
pese al 76% de fracasos RII/RIII observado a nivel parasitolo´gico.
Conclusio´n La cloroquina ha dejado de constituir una opcio´n
adecuada para tratar el paludismo clı´nico por falciparum entre los
grupos vulnerables de las a´reas estudiadas. Los altos niveles de
resistencia observados en el a´rea de Merca plantean dudas
respecto a la vida terape´utica de la sulfadoxina/pirimetamina como
agente antipalu´dico y subrayan la necesidad de identificar
alternativas adecuadas.
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